Showing results (821-830 of 5,983) with videos related to

Sort By:
Pageof 599
Molecular Cancer Therapeutics|November 13, 2008
Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinomaAngela Märten, Nina Zeiss, Susanne Serba, et al.
Molecular Cancer Therapeutics|April 16, 2009
AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cellsPedro J Beltran, Petia Mitchell, Young-A Chung, et al.
Molecular Cancer Therapeutics|July 2, 2009
Ovarian carcinoma cells with low levels of beta-F1-ATPase are sensitive to combined platinum and 2-deoxy-D-glucose treatmentEmma Hernlund, Elisabet Hjerpe, Elisabeth Avall-Lundqvist, et al.
Molecular Cancer Therapeutics|July 2, 2009
Base excision repair of reactive oxygen species-initiated 7,8-dihydro-8-oxo-2'-deoxyguanosine inhibits the cytotoxicity of platinum anticancer drugsThomas J Preston, Jeffrey T Henderson, Gordon P McCallum, et al.
Molecular Cancer Therapeutics|July 2, 2009
Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptorsXiaoqin Yuan, Xinjian Lin, Gerald Manorek, et al.
Molecular Cancer Therapeutics|April 18, 2009
DNA fingerprinting of the NCI-60 cell line panelPhilip L Lorenzi, William C Reinhold, Sudhir Varma, et al.
Molecular Cancer Therapeutics|April 18, 2009
Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4Patrizia Nanni, Giordano Nicoletti, Arianna Palladini, et al.
Molecular Cancer Therapeutics|April 18, 2009
Dual silencing of insulin-like growth factor-I receptor and epidermal growth factor receptor in colorectal cancer cells is associated with decreased proliferation and enhanced apoptosisSilke Kaulfuss, Peter Burfeind, Jochen Gaedcke, et al.
Molecular Cancer Therapeutics|April 18, 2009
KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancerJen Jen Yeh, Elizabeth D Routh, Tara Rubinas, et al.
Molecular Cancer Therapeutics|April 18, 2009
Premature senescence is a major response to DNA cross-linking agents in BRCA1-defective cells: implication for tailored treatments of BRCA1 mutation carriersManuela Santarosa, Laura Del Col, Elena Tonin, et al.
Pageof 599